Opendata, web and dolomites

PermeAbility SIGNED

PermeAbility - A non-invasive, side-effect-free diagnostic kit for intestinal disorders

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PermeAbility project word cloud

Explore the words cloud of the PermeAbility project. It provides you a very rough idea of what is the project "PermeAbility" about.

stool    poses    toxic    digestion    abdominal    informed    revealing    proprietary    threats    maintaining    bowel    health    causing    decision    syndrome    stream    blood    particles    people    biopsy    intestinal    symptoms    reported    clinical    permeability    leak    obesity    disposing    compromises    damage    mri    diarrhea    bleedings    microcapsule    bacteria    qualitative    diagnosis    reinforced    diagnostic    inflammatory    risk    rupture    pain    rheumatoid    economic    besides    compromise    articles    evaluation    unnecessary    barrier    causes    arthritis    diagnosed    ibd    markers    tightly    facts    lgs    food    wall    inflammation    disease    solely    patients    indirect    assessing    removal    plasma    direct    colonoscopy    clear    gut    select    restricted    treatment    small    dramatic    leaky    description    urges    ulcers    worldwide    though    diabetes    waste    form    life    extensive    normally    structure    acute    organization    heavy    connected    35    performed    burden    invasive    intestine    surgeries    limited    quality    lifetag    cells    billion    lesions   

Project "PermeAbility" data sheet

The following table provides information about the project.

Coordinator
LIEFTAG LDA 

Organization address
address: BIOCANT - ASSOCIACAO DE TRANSFERENCIA DE TECNOLOGI
city: CANTANHEDE
postcode: 3060 197
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Project website https://lifetag.pt
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2019-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LIEFTAG LDA PT (CANTANHEDE) coordinator 50˙000.00

Map

 Project objective

'Inflammatory Bowel Disease (IBD) is a form of acute inflammation to the small intestine that causes ulcers and extensive damage of the gut barrier causing it to rupture. This causes bleedings, abdominal pain, diarrhea, and a dramatic reduction of the quality of life. The intestinal barrier is normally a very well organised structure in which the cells are tightly connected maintaining the barrier. Moreover, IBD lesions compromise this intestinal organization and increases intestinal permeability, which is called leaky gut syndrome (LGS) being also a pre-disposing factor for several other health problems. LGS compromises digestion of food particles and removal of toxic waste products, and allows bacteria to 'leak' through the intestine to the blood stream. Besides in IBD, LGS is also common in people with health conditions such as obesity, rheumatoid arthritis and type 2 diabetes. Even though IBD poses significant threats to a patients’ health and a heavy direct and indirect economic burden, diagnosis of this condition is still limited assessing indirect parameters like general inflammation markers in plasma and stool and evaluation based by comparison on the patients symptoms description. The direct measures are also performed but are restricted to very invasive methods like biopsy or solely qualitative like MRI and microcapsule colonoscopy. In this way it is reported in several clinical articles a clear need for new diagnostic methods in IBD reinforced by facts like 35% of the performed surgeries for treatment revealing unnecessary and 1.9 billion people worldwide at risk for early lesions and IBD development not being diagnosed. In this way clinical practice urges for new methods for the assessment of lesions in the intestinal wall. Lifetag’s has developed PermeAbility, a new proprietary test to measure intestinal permeability to better select patients at high risk of IBD , leading to better informed clinical decision making, diagnosis, and treatment.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PERMEABILITY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PERMEABILITY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Read More  

MealHero (2019)

Automated cooking for tasty and healthy meals in a convenient way

Read More  

ROG (2019)

Real Organ Generation

Read More